User menu

Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis Thirty-Six-Month Results of a Randomized, Double-Blind, Controlled Trial

Bibliographic reference Saag, Kenneth G. ; Devogelaer, Jean-Pierre ; Zanchetta, Jose R. ; Adler, Robert A. ; Eastell, Richard ; et. al. Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis Thirty-Six-Month Results of a Randomized, Double-Blind, Controlled Trial. In: Arthritis & Rheumatism, Vol. 60, no. 11, p. 3346-3355 (2009)
Permanent URL
  1. , Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update, 10.1002/1529-0131(200107)44:7<1496::aid-art271>;2-5
  2. Saag Kenneth G, Glucocorticoid-induced osteoporosis, 10.1016/s0889-8529(02)00064-6
  3. Canalis E., Mazziotti G., Giustina A., Bilezikian J. P., Glucocorticoid-induced osteoporosis: pathophysiology and therapy, 10.1007/s00198-007-0394-0
  4. Rubin Mishaela R., Bilezikian John P., The Role of Parathyroid Hormone in the Pathogenesis of Glucocorticoid-Induced Osteoporosis: A Re-Examination of the Evidence, 10.1210/jc.2002-012101
  5. Van Staa T. P., Leufkens H. G. M., Abenhaim L., Zhang B., Cooper C., Use of Oral Corticosteroids and Risk of Fractures, 10.1359/jbmr.2000.15.6.993
  6. Van Staa T. P., Laan R. F., Barton I. P., Cohen S., Reid D. M., Cooper C., Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy, 10.1002/art.11283
  7. Kanis John A, Johansson Helena, Oden Anders, Johnell Olof, de Laet Chris, Melton L Joseph, Tenenhouse Alan, Reeve Jonathan, Silman Alan J, Pols Huibert AP, Eisman John A, McCloskey Eugene V, Mellstrom Dan, A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk, 10.1359/jbmr.040134
  8. Royal College of Physicians
  9. Devogelaer Jean-Pierre, Goemaere Stefan, Boonen Steven, Body Jean-Jacques, Kaufman Jean-Marc, Reginster Jean-Yves, Rozenberg Serge, Boutsen Yves, Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club, 10.1007/s00198-005-2032-z
  10. Neer Robert M., Arnaud Claude D., Zanchetta Jose R., Prince Richard, Gaich Gregory A., Reginster Jean-Yves, Hodsman Anthony B., Eriksen Erik F., Ish-Shalom Sophia, Genant Harry K., Wang Ouhong, Mellström Dan, Oefjord Erik S., Marcinowska-Suchowierska Ewa, Salmi Jorma, Mulder Henk, Halse Johan, Sawicki Andrzej Z., Mitlak Bruce H., Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis, 10.1056/nejm200105103441904
  11. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman J-M, Clancy AD, Gaich GA, The Effect of Teriparatide [Human Parathyroid Hormone (1-34)] Therapy on Bone Density in Men With Osteoporosis, 10.1359/jbmr.2003.18.1.9
  12. Jiang Yebin, Zhao Jenny J, Mitlak Bruce H, Wang Ouhong, Genant Harry K, Eriksen Erik F, Recombinant Human Parathyroid Hormone (1-34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure, 10.1359/jbmr.2003.18.11.1932
  13. Canalis Ernesto, Giustina Andrea, Bilezikian John P., Mechanisms of Anabolic Therapies for Osteoporosis, 10.1056/nejmra067395
  14. Dobnig H, Turner R T, Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells., 10.1210/endo.136.8.7628403
  15. Jilka Robert L., Weinstein Robert S., Bellido Teresita, Roberson Paula, Parfitt A. Michael, Manolagas Stavros C., Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone, 10.1172/jci6610
  16. Lane N E, Sanchez S, Modin G W, Genant H K, Pierini E, Arnaud C D, Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial., 10.1172/jci3914
  17. Rehman Q., Lang T.F., Arnaud C.D., Modin G.W., Lane N.E., Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis, 10.1007/s00198-002-1312-0
  18. Saag Kenneth G., Shane Elizabeth, Boonen Steven, Marín Fernando, Donley David W., Taylor Kathleen A., Dalsky Gail P., Marcus Robert, Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis, 10.1056/nejmoa071408
  19. Genant, J Bone Miner Res, 8, 1137 (1993)
  20. Westfall Peter H., Krishen Alok, Optimally weighted, fixed sequence and gatekeeper multiple testing procedures, 10.1016/s0378-3758(01)00077-5
  21. Cohen Stanley, Levy Robert M., Keller Michael, Boling Eugene, Emkey Ronald D., Greenwald Maria, Zizic Thomas M., Wallach Stanley, Sewell Kathryn L., Lukert Barbara P., Axelrod Douglas W., Chines Arkadi A., Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, 10.1002/1529-0131(199911)42:11<2309::aid-anr8>;2-k
  22. Saag Kenneth G., Emkey Ronald, Schnitzer Thomas J., Brown Jacques P., Hawkins Federico, Goemaere Stefan, Thamsborg Gorm, Liberman Uri A., Delmas Pierre D., Malice Marie-Pierre, Czachur Michelle, Daifotis Anastasia G., Lane Nancy, Correa-Rotter Ricardo, Yanover Melissa, Westhovens Rene, Epstein Sol, Adachi Jonathan D., Poubelle Patrice, Melo-Gomes Jose, Rodriguez-Portales Jose A., Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis, 10.1056/nejm199807303390502
  23. Adachi Jonathan D., Saag Kenneth G., Delmas Pierre D., Liberman Uri A., Emkey Ronald D., Seeman Ego, Lane Nancy E., Kaufman Jean-Marc, Poubelle Patrice E. E., Hawkins Federico, Correa-Rotter Ricardo, Menkes Charles-Joel, Rodriguez-Portales Jose A., Schnitzer Thomas J., Block Joel A., Wing Jeffrey, McIlwain Harris H., Westhovens Rene, Brown Jacques, Melo-Gomes Jose A., Gruber Barry L., Yanover Melissa J., Leite Maria Odette R., Siminoski Kerry G., Nevitt Michael C., Sharp John T., Malice Marie-Pierre, Dumortier Thomas, Czachur Michelle, Carofano Wendy, Daifotis Anastasia, Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial, 10.1002/1529-0131(200101)44:1<202::aid-anr27>;2-w
  24. Reid David M., Hughes Rodney A., Laan Roland F. J. M., Sacco-Gibson Nancy A., Wenderoth Dietrich H., Adami Silvano, Eusebio Rachelle A., Devogelaer Jean-Pierre, Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized Trial, 10.1359/jbmr.2000.15.6.1006
  25. Ringe J. D., Dorst A., Faber H., Ibach K., Sorenson F., Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study, 10.1007/s00198-003-1425-0
  26. Szulc P., Delmas P. D., Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis, 10.1007/s00198-008-0660-9
  27. McClung Michael R., San Martin Javier, Miller Paul D., Civitelli Roberto, Bandeira Francisco, Omizo Molly, Donley David W., Dalsky Gail P., Eriksen Erik F., Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass, 10.1001/archinte.165.15.1762
  28. Rubin Mishaela R, Bilezikian John P, The anabolic effects of parathyroid hormone therapy, 10.1016/s0749-0690(02)00074-5
  29. Dempster David W., Cosman Felicia, Kurland Etah S., Zhou Hua, Nieves Jeri, Woelfert Lillian, Shane Elizabeth, Plavetić Katarina, Müller Ralph, Bilezikian John, Lindsay Robert, Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study*, 10.1359/jbmr.2001.16.10.1846
  30. Black Dennis M., Thompson Desmond E., Bauer Douglas C., Ensrud Kris, Musliner Thomas, Hochberg Marc C., Nevitt Michael C., Suryawanshi Shailaja, Cummings Steven R., Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial, 10.1210/jcem.85.11.6953
  31. Liberman Uri A., Weiss Stuart R., Bröll Johann, Minne Helmut W., Quan Hui, Bell Norman H., Rodriguez-Portales Jose, Downs Robert W., Dequeker Jan, Favus Murray, Seeman Ego, Recker Robert R., Capizzi Thomas, Santora Arthur C., Lombardi Antonio, Shah Raksha V., Hirsch Laurence J., Karpf David B., Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis, 10.1056/nejm199511303332201
  32. McDonough Allyson K, Curtis Jeffrey R, Saag Kenneth G, The epidemiology of glucocorticoid-associated adverse events : , 10.1097/bor.0b013e3282f51031
  33. Manolagas Stavros C., Weinstein Robert S., New Developments in the Pathogenesis and Treatment of Steroid-Induced Osteoporosis, 10.1359/jbmr.1999.14.7.1061